Murine breast tumors induce systemic alterations of the B cell compartment

NICOLÁS SARBIA; MONTANA N. MANSELLE COCCO; VERONICA C MARTINEZ ALLO; SABRINA GATTO; ROSA M. MORALES; TOMAS D'ALOTTO-MORENO; GABRIEL A RABINOVICH; MARIANA SALATINO; MARTA A .TOSCANO

San Pablo

Conferencia; Second AACR International Conference; 2018

AACR LACOG

Anti-tumor immunity has been a matter of extensive research for several years, resulting in highly effective immunotherapies widely used against numeroustypes of cancer. While the roles of T cells and myeloid cells have been broadly studied, B cell function is still not thoroughly understood. In order to determine if the presence of malignant tumors has an impact over the B cell compartment, we analyzed by flow cytometry the frequency and number of the different B cell subsets in the bone marrow and spleen of BALB/cJ tumor-free mice and compared it to tumor-bearing mice of the same strain. We chose two murine models of breast cancer that better recapitulate the two types of human breast cancer with more chances of responding to immunotherapy: a triple negative breast cell line (4T1) and a HER2+ cell line (LM3). To begin with, we found a dramatic reduction in the number of B220+ CD19+ B cells (p